Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperphosphatemia In Chronic Kidney Disease - Drugs In Development, 2022, provides an overview of the Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline landscape.
Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus and rash. Treatment includes phosphate binders and diuretics.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperphosphatemia In Chronic Kidney Disease - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 3, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).
- The pipeline guide reviews pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hyperphosphatemia In Chronic Kidney Disease - Overview
Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperphosphatemia In Chronic Kidney Disease - Companies Involved in Therapeutics Development
Ardelyx Inc
China Nuokang Bio-Pharmaceutical Inc
Citragen Pharmaceuticals Inc
OPKO Health Inc
Panion & Bf Biotech Inc
Shield Therapeutics Plc
Unicycive Therapeutics Inc
Vidasym Inc
Vifor Pharma Ltd
Hyperphosphatemia In Chronic Kidney Disease - Drug Profiles
CGN-002 - Drug Profile
Product Description
Mechanism Of Action
fermagate - Drug Profile
Product Description
Mechanism Of Action
ferric citrate - Drug Profile
Product Description
Mechanism Of Action
lanthanum dioxycarbonate - Drug Profile
Product Description
Mechanism Of Action
lanthanum polystyrene sulfonate - Drug Profile
Product Description
Mechanism Of Action
PT-20 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Hyperphosphatemia - Drug Profile
Product Description
Mechanism Of Action
succharated ferric oxide - Drug Profile
Product Description
Mechanism Of Action
tenapanor hydrochloride - Drug Profile
Product Description
Mechanism Of Action
VS-501 - Drug Profile
Product Description
Mechanism Of Action
Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects
Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products
Hyperphosphatemia In Chronic Kidney Disease - Product Development Milestones
Featured News & Press Releases
Nov 10, 2022: Unicycive completes enrollment of pivotal bioequivalence study for RENAZORB (lanthanum dioxycarbonate), an investigational treatment for hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis
Nov 06, 2022: Unicycive Therapeutics announces abstract on Renazorb selected for presentation at American Society of Nephrology’s Kidney Week 2022
Feb 02, 2022: Unicycive announces Renazorb pre-clinical and clinical data selected for presentation at National Kidney Foundation Spring Clinical Meeting
Nov 29, 2021: Unicycive Therapeutics receives confirmatory guidance on renazorb regulatory pathway
Dec 09, 2020: Akebiashares program: current approaches for managing hyperphosphatemia and caring for patients via telehealth
Jan 28, 2019: Velphoro doubles percentage of patients reaching target serum phosphorous levels in new study published in Journal of Renal Nutrition
Jan 06, 2017: Shield Therapeutics Provides Update on PT20
Oct 14, 2016: Keryx Biopharmaceuticals Announces Presentations of Data at the American Society of Nephrology Kidney Week 2016 Annual Meeting
Sep 24, 2015: Keryx Receives European Approval for Fexeric (ferric citrate coordination complex) for the Treatment of Hyperphosphatemia in Adults With Chronic Kidney Disease
May 07, 2015: Phosphate Therapeutics announces positive results in the PEACH pivotal study of its novel phosphate binder (PT20) for the treatment of hyperphosphataemia
Mar 04, 2015: Keryx Biopharmaceuticals Announces Publication of Auryxia (ferric citrate) Analysis in Journal of the American Society of Nephrology
Jan 09, 2015: Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch
Nov 17, 2014: Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate
Nov 15, 2014: Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study
Oct 01, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Ardelyx Inc, 2022
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by China Nuokang Bio-Pharmaceutical Inc, 2022
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Citragen Pharmaceuticals Inc, 2022
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by OPKO Health Inc, 2022
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Panion & Bf Biotech Inc, 2022
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Shield Therapeutics Plc, 2022
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Unicycive Therapeutics Inc, 2022
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Vidasym Inc, 2022
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Vifor Pharma Ltd, 2022
Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects, 2022
Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products, 2022
List of Figures
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
